study_id,first_author,year,doi,target_trial_name,target_trial_reg_no,target_trial_doi,population,intervention,comparison,outcome,outcome_type,effect_measure,rct_estimate,rct_lb,rct_ub,tte_estimate,tte_lb,tte_ub,tte_rct_diff_estimate,tte_rct_diff_lb,tte_rct_diff_ub,rct2_estimate,rct2_lb,rct2_ub,rct3_estimate,rct3_lb,rct3_ub,rct4_estimate,rct4_lb,rct4_ub
,Admon,2019,https://doi.org/10.1513/AnnalsATS.201903-241OC,PreVent,NCT03026322,https://doi.org/10.1056/NEJMoa1812405,patients undergoing tracheal intubation,positive-pressure ventilation with a bag- mask device or noninvasive ventilator (modi ed RSI),"No positive-pressure ventilation except after a failed attempt or for SpO2 ,90% (classic RSI)",lowest oxygen saturation %,Efficacy,MD,3.9,1.4,6.4,1.8,-1,4.6,,,,,,,,,,,,
,Admon,2019,https://doi.org/10.1513/AnnalsATS.201903-241OC,PreVent,NCT03026322,https://doi.org/10.1056/NEJMoa1812405,patients undergoing tracheal intubation,positive-pressure ventilation with a bag- mask device or noninvasive ventilator (modi ed RSI),"No positive-pressure ventilation except after a failed attempt or for SpO2 ,90% (classic RSI)",lowest oxygen saturation <80%,Efficacy,RR,0.48,0.3,0.77,0.6,0.38,0.93,,,,,,,,,,,,
,Admon,2019,https://doi.org/10.1513/AnnalsATS.201903-241OC,PreVent,NCT03026322,https://doi.org/10.1056/NEJMoa1812405,patients undergoing tracheal intubation,positive-pressure ventilation with a bag- mask device or noninvasive ventilator (modi ed RSI),"No positive-pressure ventilation except after a failed attempt or for SpO2 ,90% (classic RSI)",lowest oxygen saturation <90%,Efficacy,RR,0.74,0.6,1,0.89,0.7,1.2,,,,,,,,,,,,
,Admon,2019,https://doi.org/10.1513/AnnalsATS.201903-241OC,PreVent,NCT03026322,https://doi.org/10.1056/NEJMoa1812405,patients undergoing tracheal intubation,positive-pressure ventilation with a bag- mask device or noninvasive ventilator (modi ed RSI),"No positive-pressure ventilation except after a failed attempt or for SpO2 ,90% (classic RSI)",lowest oxygen saturation <70%,Efficacy,RR,0.63,0.3,1.3,0.41,0.2,0.9,,,,,,,,,,,,
,Admon,2019,https://doi.org/10.1513/AnnalsATS.201903-241OC,PreVent,NCT03026322,https://doi.org/10.1056/NEJMoa1812405,patients undergoing tracheal intubation,positive-pressure ventilation with a bag- mask device or noninvasive ventilator (modi ed RSI),"No positive-pressure ventilation except after a failed attempt or for SpO2 ,90% (classic RSI)",Decrease in oxygen saturation %,Efficacy,MD,-1.9,-4.5,0.8,-4.5,-6.8,-2.2,,,,,,,,,,,,
,Admon,2019,https://doi.org/10.1513/AnnalsATS.201903-241OC,PreVent,NCT03026322,https://doi.org/10.1056/NEJMoa1812405,patients undergoing tracheal intubation,positive-pressure ventilation with a bag- mask device or noninvasive ventilator (modi ed RSI),"No positive-pressure ventilation except after a failed attempt or for SpO2 ,90% (classic RSI)",Operator-reported aspiration,Safety,RR,3,0.4,10.8,0.64,0.2,1.9,,,,,,,,,,,,
,Admon,2019,https://doi.org/10.1513/AnnalsATS.201903-241OC,PreVent,NCT03026322,https://doi.org/10.1056/NEJMoa1812405,patients undergoing tracheal intubation,positive-pressure ventilation with a bag- mask device or noninvasive ventilator (modi ed RSI),"No positive-pressure ventilation except after a failed attempt or for SpO2 ,90% (classic RSI)",Cardiac arrest 1 h after intubation,Safety,RR,2,0.4,10.8,0.76,0.2,3.4,,,,,,,,,,,,
,Admon,2019,https://doi.org/10.1513/AnnalsATS.201903-241OC,PreVent,NCT03026322,https://doi.org/10.1056/NEJMoa1812405,patients undergoing tracheal intubation,positive-pressure ventilation with a bag- mask device or noninvasive ventilator (modi ed RSI),"No positive-pressure ventilation except after a failed attempt or for SpO2 ,90% (classic RSI)",Ventilator-free days,Efficacy,MD,-0.5,-3,1.9,0.6,-1.7,2.9,,,,,,,,,,,,
,Admon,2019,https://doi.org/10.1513/AnnalsATS.201903-241OC,PreVent,NCT03026322,https://doi.org/10.1056/NEJMoa1812405,patients undergoing tracheal intubation,positive-pressure ventilation with a bag- mask device or noninvasive ventilator (modi ed RSI),"No positive-pressure ventilation except after a failed attempt or for SpO2 ,90% (classic RSI)",ICU-free days,Efficacy,MD,0.1,-2.2,2.4,0.8,-1.3,2.9,,,,,,,,,,,,
,Admon,2019,https://doi.org/10.1513/AnnalsATS.201903-241OC,PreVent,NCT03026322,https://doi.org/10.1056/NEJMoa1812405,patients undergoing tracheal intubation,positive-pressure ventilation with a bag- mask device or noninvasive ventilator (modi ed RSI),"No positive-pressure ventilation except after a failed attempt or for SpO2 ,90% (classic RSI)",Died before hospital discharge,Efficacy,RR,1,0.8,1.3,1,0.8,1.3,,,,,,,,,,,,
,Althunian,2020,https://doi.org/10.1002/pds.5065,Rocket AF,NCT00403767,https://doi.org/10.1056/NEJMoa1009638,patients with atrial fibrillation,rivaroxaban,warfarin,"stroke, systemic emoblism prevention",Efficacy,HR,0.88,0.75,1.03,1.04,0.84,1.3,,,,,,,,,,,,
,Althunian,2020,https://doi.org/10.1002/pds.5065,Rocket AF,NCT00403767,https://doi.org/10.1056/NEJMoa1009638,patients with atrial fibrillation,rivaroxaban,warfarin,"stroke, systemic emoblism, death",Efficacy,HR,0.86,0.74,0.99,1.18,1.03,1.34,,,,,,,,,,,,
,Althunian,2020,https://doi.org/10.1002/pds.5065,Rocket AF,NCT00403767,https://doi.org/10.1056/NEJMoa1009638,patients with atrial fibrillation,rivaroxaban,warfarin,major bleeding,Efficacy,HR,1.04,0.9,1.2,1.07,0.95,1.21,,,,,,,,,,,,
,Szummer,2020,https://doi.org/10.1161/circulationaha.120.050645,PLATO,NCT00391872,https://doi.org/10.1056/nejmoa0904327,patients ≥80 years of age and alive at discharge who had a MI registered for the first time in SWEDEHEART,Clopidogrel,Ticagrelor,"CV Death, MI, Stroke",Efficacy,HR,0.89,0.74,1.08,0.97,0.88,1.06,,,,,,,,,,,,
,Szummer,2020,https://doi.org/10.1161/circulationaha.120.050645,PLATO,NCT00391872,https://doi.org/10.1056/nejmoa0904327,patients ≥80 years of age and alive at discharge who had a MI registered for the first time in SWEDEHEART,Clopidogrel,Ticagrelor,Myocardial infarction,Efficacy,HR,0.96,0.74,1.25,0.8,0.7,0.92,,,,,,,,,,,,
,Szummer,2020,https://doi.org/10.1161/circulationaha.120.050645,PLATO,NCT00391872,https://doi.org/10.1056/nejmoa0904327,patients ≥80 years of age and alive at discharge who had a MI registered for the first time in SWEDEHEART,Clopidogrel,Ticagrelor,Stroke,Efficacy,HR,1.58,0.93,2.7,0.72,0.56,0.93,,,,,,,,,,,,
,Szummer,2020,https://doi.org/10.1161/circulationaha.120.050645,PLATO,NCT00391872,https://doi.org/10.1056/nejmoa0904327,patients ≥80 years of age and alive at discharge who had a MI registered for the first time in SWEDEHEART,Clopidogrel,Ticagrelor,(readmission for) major bleeding,Efficacy,HR,1.02,0.82,1.27,1.48,1.25,1.76,,,,,,,,,,,,
,Petito,2020,https://doi.org/10.1001/jamanetworkopen.2020.0452,QUASAR,NA,https://doi.org/10.1016/S0140-6736(07)61866-2,patients with stage II colorectal cancer,fluorouracil initiation within 3 months of tumor resection,no fluorouracil initiation,Overall survival,Efficacy,HR,1.02,0.7,1.48,1.01,0.97,1.05,,,,,,,,,,,,
,Petito,2020,https://doi.org/10.1001/jamanetworkopen.2020.0452,NCIC CTG PA.3,NA,https://doi.org/10.1200/jco.2006.07.9525,patients with advanced pancreatic adenocarcinoma,erlotinib initiation within 12 weeks of gemcitabine,no erlotinib initiation,Overall survival,Efficacy,HR,0.96,0.74,1.24,1.03,0.96,1.09,,,,,,,,,,,,
,Bacic,2020,https://doi.org/10.1016/j.urology.2020.01.039,EORTC 30881,NA,https://doi.org/10.1016/j.eururo.2008.09.052,patients with cT1-3cN0cM0 renal cell carcinoma,radical nephrectomy with lymph node dissection,radical nephrectomy alone,Overall survival,Efficacy,HR,1.02,0.8,1.29,1.13,1.07,1.2,,,,,,,,,,,,
,Kirchgesner,2021,https://doi.org/10.1002/cpt.2304,SONIC,NCT00094458,https://doi.org/10.1056/NEJMoa0904492,patients with Crohn's disease,vedolizumab + thiopurines,vedolizumab monotherapy,"Treatment failure, 26 weeks",Efficacy,RR,0.78,0.62,0.97,0.71,0.62,0.82,,,,,,,,,,,,
,Kirchgesner,2021,https://doi.org/10.1002/pds.5356,UC SUCCESS,NCT00537316,https://doi.org/10.1053/j.gastro.2013.10.052,patients with ulcerative colitis,infliximab plus thiopurines,infliximab monotherapy,"Treatment failure, 16 weeks",Efficacy,RR,0.77,0.62,0.96,0.73,0.6,0.9,,,,,,,,,,,,
,Matthews,2021,https://doi.org/10.1161/jaha.120.020357,VALIDATE,NCT02311231,https://doi.org/10.1056/nejmoa1706443,patients undergoing percutaneous coronary intervention in Sweden,bivalirudin,heparin,"Composite of death from any cause, MI, or major bleeding events by 180 days",Efficacy,RR,0.96,0.83,1.1,0.93,0.77,1.12,,,,,,,,,,,,
,Matthews,2021,https://doi.org/10.1161/jaha.120.020357,VALIDATE,NCT02311231,https://doi.org/10.1056/nejmoa1706443,patients undergoing percutaneous coronary intervention in Sweden,bivalirudin,heparin,Death by 180 days,Efficacy,RR,1.05,0.78,1.41,1.21,0.88,1.68,,,,,,,,,,,,
,Matthews,2021,https://doi.org/10.1161/jaha.120.020357,VALIDATE,NCT02311231,https://doi.org/10.1056/nejmoa1706443,patients undergoing percutaneous coronary intervention in Sweden,bivalirudin,heparin,MI by 180 days,Efficacy,RR,0.84,0.6,1.19,1.08,0.76,1.54,,,,,,,,,,,,
,Matthews,2021,https://doi.org/10.1161/jaha.120.020357,VALIDATE,NCT02311231,https://doi.org/10.1056/nejmoa1706443,patients undergoing percutaneous coronary intervention in Sweden,bivalirudin,heparin,Major bleeding by 180 days,Efficacy,RR,1,0.84,1.19,0.69,0.5,0.95,,,,,,,,,,,,
,Yiu,2021,https://doi.org/10.1001/jamadermatol.2020.4202,CLEAR,NCT02074982,"https://doi.org/10.1016/j.jaad.2015.05.013, https://doi.org/10.1016/j.jaad.2016.08.008",patients with chronic plaque psoriasis aged > 18 years with PASI ≥ 12,secukinumab,ustekinumab,PASI<=2 after 12 months,Efficacy,RR,1.24,1.11,1.37,1.28,1.06,1.55,,,,,,,,,,,,
,Weberpals,2021,https://doi.org/10.1097/ede.0000000000001338,PRONOUNCE,NCT00948675,https://doi.org/10.1097/jto.0000000000000366,patients with advanced nonsquamous non-small-cell lung cancer,carboplatin/pemetrexed followed by pemetrexed maintenance,bevacizumab/carboplatin/paclitaxel followed by bevacizumab maintenance,Overall survival,Efficacy,HR,1.07,0.83,1.36,1.09,0.87,1.37,,,,,,,,,,,,
,Jang,2022,https://doi.org/10.3390/ijerph192013560,ASPIRE,NCT01080391,https://doi.org/10.1056/nejmoa1411321,Korean patients with relapsed/refractory multiple myeloma (RRMM) aged ≥18 years,"KRd (carfilzomib, lenalidomide, and dexamethasone)",Rd (lenalidomide and dexamethasone),Acute renal failure,Safety,RR,1.19,0.7,2,1.3,0.53,3.16,,,,,,,,,,,,
,Jang,2022,https://doi.org/10.3390/ijerph192013560,ASPIRE,NCT01080391,https://doi.org/10.1056/nejmoa1411321,Korean patients with relapsed/refractory multiple myeloma (RRMM) aged ≥18 years,"KRd (carfilzomib, lenalidomide, and dexamethasone)",Rd (lenalidomide and dexamethasone),Heart failure,Safety,RR,1.59,0.83,3.02,1.45,0.61,3.48,,,,,,,,,,,,
,Jang,2022,https://doi.org/10.3390/ijerph192013560,ASPIRE,NCT01080391,https://doi.org/10.1056/nejmoa1411321,Korean patients with relapsed/refractory multiple myeloma (RRMM) aged ≥18 years,"KRd (carfilzomib, lenalidomide, and dexamethasone)",Rd (lenalidomide and dexamethasone),Ischemic heart disease,Safety,RR,1.28,0.68,2.42,1,0.34,2.92,,,,,,,,,,,,
,Jang,2022,https://doi.org/10.3390/ijerph192013560,ASPIRE,NCT01080391,https://doi.org/10.1056/nejmoa1411321,Korean patients with relapsed/refractory multiple myeloma (RRMM) aged ≥18 years,"KRd (carfilzomib, lenalidomide, and dexamethasone)",Rd (lenalidomide and dexamethasone),Cough,Safety,RR,1.94,1.37,2.72,1.04,0.45,2.45,,,,,,,,,,,,
,Jang,2022,https://doi.org/10.3390/ijerph192013560,ASPIRE,NCT01080391,https://doi.org/10.1056/nejmoa1411321,Korean patients with relapsed/refractory multiple myeloma (RRMM) aged ≥18 years,"KRd (carfilzomib, lenalidomide, and dexamethasone)",Rd (lenalidomide and dexamethasone),Dyspenia,Safety,RR,1.38,0.94,2,2.27,1.24,4.16,,,,,,,,,,,,
,Jang,2022,https://doi.org/10.3390/ijerph192013560,ASPIRE,NCT01080391,https://doi.org/10.1056/nejmoa1411321,Korean patients with relapsed/refractory multiple myeloma (RRMM) aged ≥18 years,"KRd (carfilzomib, lenalidomide, and dexamethasone)",Rd (lenalidomide and dexamethasone),Hypokalemia,Safety,RR,2.46,1.69,3.57,1.91,0.62,5.87,,,,,,,,,,,,
,Jang,2022,https://doi.org/10.3390/ijerph192013560,ASPIRE,NCT01080391,https://doi.org/10.1056/nejmoa1411321,Korean patients with relapsed/refractory multiple myeloma (RRMM) aged ≥18 years,"KRd (carfilzomib, lenalidomide, and dexamethasone)",Rd (lenalidomide and dexamethasone),Muscle spasm,Safety,RR,1.36,0.97,1.89,5.12,1.05,15,,,,,,,,,,,,
,Jang,2022,https://doi.org/10.3390/ijerph192013560,ASPIRE,NCT01080391,https://doi.org/10.1056/nejmoa1411321,Korean patients with relapsed/refractory multiple myeloma (RRMM) aged ≥18 years,"KRd (carfilzomib, lenalidomide, and dexamethasone)",Rd (lenalidomide and dexamethasone),Thrombocytopenia,Safety,RR,1.4,1.02,1.94,1.84,1.1,3.06,,,,,,,,,,,,
,Jang,2022,https://doi.org/10.3390/ijerph192013560,ASPIRE,NCT01080391,https://doi.org/10.1056/nejmoa1411321,Korean patients with relapsed/refractory multiple myeloma (RRMM) aged ≥18 years,"KRd (carfilzomib, lenalidomide, and dexamethasone)",Rd (lenalidomide and dexamethasone),Diarrhea,Safety,RR,1.44,1.08,1.92,1.03,0.52,1.99,,,,,,,,,,,,
,Jang,2022,https://doi.org/10.3390/ijerph192013560,ASPIRE,NCT01080391,https://doi.org/10.1056/nejmoa1411321,Korean patients with relapsed/refractory multiple myeloma (RRMM) aged ≥18 years,"KRd (carfilzomib, lenalidomide, and dexamethasone)",Rd (lenalidomide and dexamethasone),Hypertension,Safety,RR,2.23,1.38,3.62,1.32,0.73,2.4,,,,,,,,,,,,
,Jang,2022,https://doi.org/10.3390/ijerph192013560,ASPIRE,NCT01080391,https://doi.org/10.1056/nejmoa1411321,Korean patients with relapsed/refractory multiple myeloma (RRMM) aged ≥18 years,"KRd (carfilzomib, lenalidomide, and dexamethasone)",Rd (lenalidomide and dexamethasone),Pyrexia,Safety,RR,1.52,1.08,2.11,1.79,0.97,3.24,,,,,,,,,,,,
,Jang,2022,https://doi.org/10.3390/ijerph192013560,ASPIRE,NCT01080391,https://doi.org/10.1056/nejmoa1411321,Korean patients with relapsed/refractory multiple myeloma (RRMM) aged ≥18 years,"KRd (carfilzomib, lenalidomide, and dexamethasone)",Rd (lenalidomide and dexamethasone),Upper respiratory tract infection,Safety,RR,1.68,1.19,2.33,1.43,0.59,3.56,,,,,,,,,,,,
,Matthews,2022,https://doi.org/10.1093/aje/kwac098,TASTE,NCT01093404,"https://doi.org/10.1056/NEJMoa1308789, https://doi.org/10.1056/NEJMoa1405707",Adults (≥18 years) with ST-elevation myocardial infarction (STEMI) requiring percutaneous coronary intervention (PCI),Thrombus aspiration followed by PCI,PCI without thrombus aspiration,Death,Efficacy,RR,0.94,0.78,1.15,1.09,0.96,1.24,,,,,,,,,,,,
,Matthews,2022,https://doi.org/10.1093/aje/kwac098,TASTE,NCT01093404,"https://doi.org/10.1056/NEJMoa1308789, https://doi.org/10.1056/NEJMoa1405707",Adults (≥18 years) with ST-elevation myocardial infarction (STEMI) requiring percutaneous coronary intervention (PCI),Thrombus aspiration followed by PCI,PCI without thrombus aspiration,Myocardial infarction,Efficacy,RR,0.97,0.73,1.28,0.96,0.79,1.17,,,,,,,,,,,,
,Kuehne,2022,https://doi.org/10.1016/j.jclinepi.2022.10.005,MRC OV05/EORTC 55955,ISRCTN87786644,https://doi.org/10.1016/S0140-6736(10)61268-8,"Female patients aged ≥18 years with ovarian, fallopian tube, or primary peritoneal cancer who had disease progression after first-line chemotherapy (LOT1)","Second-line chemotherapy (LOT2): KRd regimen (carfilzomib, lenalidomide, and dexamethasone)",Delayed LOT2 (started >6 weeks after progression),Overall survival,Efficacy,HR,1.01,0.82,1.25,1.12,0.96,1.28,,,,,,,,,,,,
,Barbulescu,2022,https://doi.org/10.1002/cpt.2673,SWEFOT,CT20080004,https://doi.org/10.1016/s0140-6736(09)60944-2,Patients with rheumatoid arthritis (RA),Infliximab added to methotrexate therapy,Sulfasalazine (SSZ) + hydroxychloroquine (HCQ) added to methotrexate therapy,European Alliance of Associations for Rheumatology (EULAR) good responders at 9 months,Efficacy,RR,1.59,1.1,2.3,1.48,0.98,2.24,,,,,,,,,,,,
,Barbulescu,2022,https://doi.org/10.1002/cpt.2673,SWEFOT,CT20080004,https://doi.org/10.1016/s0140-6736(09)60944-2,Patients with rheumatoid arthritis (RA),Infliximab added to methotrexate therapy,Sulfasalazine (SSZ) + hydroxychloroquine (HCQ) added to methotrexate therapy,European Alliance of Associations for Rheumatology (EULAR) good or moderate responders at 9 months,Efficacy,RR,1.22,0.98,1.53,1.27,0.99,1.63,,,,,,,,,,,,
,Jin,2022,https://doi.org/10.1016/j.joca.2022.06.005,"Sanghi et al., McAlindon et al., Arden et al., Jin et al.","NA, NCT00306774, ISRCTN94818153, NCT01176344","https://doi.org/10.1007/s11999-013-3201-6, https://doi.org/10.1001/jama.2012.164487, https://doi.org/10.1016/j.joca.2016.05.020, https://doi.org/10.1001/jama.2016.1961",Patients aged ≥45 years with symptomatic knee osteoarthritis (KOA),"Daily vitamin D supplementation of 1,000 IU for at least 4 days/week in the past 30 days",No vitamin D supplementation in the past 30 days,Change in WOMAC function score at 24 months,Efficacy,SMD,-0.92,-1.32,-0.51,0.02,-0.11,0.15,,,,-0.3,-0.62,0.03,-0.26,-0.46,-0.07,-0.08,-0.26,0.1
,Jin,2022,https://doi.org/10.1016/j.joca.2022.06.005,"Sanghi et al., McAlindon et al., Arden et al., Jin et al.","NA, NCT00306774, ISRCTN94818153, NCT01176344","https://doi.org/10.1007/s11999-013-3201-6, https://doi.org/10.1001/jama.2012.164487, https://doi.org/10.1016/j.joca.2016.05.020, https://doi.org/10.1001/jama.2016.1961",Patients aged ≥45 years with symptomatic knee osteoarthritis (KOA),"Daily vitamin D supplementation of 1,000 IU for at least 4 days/week in the past 30 days",No vitamin D supplementation in the past 30 days,Change in WOMAC pain score at 24 months,Efficacy,SMD,-0.39,-0.78,0,0.08,-0.07,0.23,,,,-0.23,-0.55,0.1,-0.16,-0.35,0.03,-0.09,-0.28,0.09
,Chen,2022,https://doi.org/10.1200/cci.21.00195,Cutsem et al.,NCT00154102,https://doi.org/10.1200/jco.2010.33.5091,Patients with metastatic colorectal cancer,Cetuximab + FOLFIRI,FOLFIRI alone,Death,Efficacy,HR,0.93,0.81,1.07,0.86,0.68,1.07,,,,,,,,,,,,
,Chen,2022,https://doi.org/10.1200/cci.21.00195,Peeters et al.,NCT00339183,https://doi.org/10.1158/1078-0432.ccr-15-0526,Patients with metastatic colorectal cancer,Panitumumab + FOLFIRI,FOLFIRI alone,Death,Efficacy,HR,0.96,0.75,1.23,0.89,0.68,1.38,,,,,,,,,,,,
,Hou,2022,https://doi.org/10.1001/jamanetworkopen.2022.18371,COST,NCT00002575,https://doi.org/10.1056/NEJMoa032651,Adult patients (≥18 years) with early-stage (stages I-III) colon cancer who underwent colectomy,Laparoscopy-assisted colectomy (LAC),Open colectomy (OC),5-year overall survival,Efficacy,RD,0.006,-0.169,0.183,-0.007,-0.07,0.057,-0.013,-0.077,0.093,,,,,,,,,
,Jang,2022,https://doi.org/10.3389/fphar.2022.928121,EMPA-REG OUTCOME,NCT01131676,https://doi.org/10.1056/NEJMoa1504720,Adult patients (≥18 years) with type 2 diabetes mellitus and established cardiovascular disease in Korean population,Empagliflozin,Sitagliptin,MACE (major adverse cardiovascular events),Efficacy,HR,0.86,0.74,0.99,0.87,0.79,0.96,,,,,,,,,,,,
,Jang,2022,https://doi.org/10.3389/fphar.2022.928121,EMPA-REG OUTCOME,NCT01131676,https://doi.org/10.1056/NEJMoa1504720,Adult patients (≥18 years) with type 2 diabetes mellitus and established cardiovascular disease in Korean population,Empagliflozin,Sitagliptin,All cause death,Efficacy,HR,0.68,0.57,0.82,0.78,0.67,0.91,,,,,,,,,,,,
,Jang,2022,https://doi.org/10.3389/fphar.2022.928121,EMPA-REG OUTCOME,NCT01131676,https://doi.org/10.1056/NEJMoa1504720,Adult patients (≥18 years) with type 2 diabetes mellitus and established cardiovascular disease in Korean population,Empagliflozin,Sitagliptin,Myocardial infarction,Efficacy,HR,0.87,0.7,1.09,0.91,0.76,1.08,,,,,,,,,,,,
,Jang,2022,https://doi.org/10.3389/fphar.2022.928121,EMPA-REG OUTCOME,NCT01131676,https://doi.org/10.1056/NEJMoa1504720,Adult patients (≥18 years) with type 2 diabetes mellitus and established cardiovascular disease in Korean population,Empagliflozin,Sitagliptin,Stroke,Efficacy,HR,1.18,0.89,1.56,0.89,0.75,1.05,,,,,,,,,,,,
,Jang,2022,https://doi.org/10.3389/fphar.2022.928121,EMPA-REG OUTCOME,NCT01131676,https://doi.org/10.1056/NEJMoa1504720,Adult patients (≥18 years) with type 2 diabetes mellitus and established cardiovascular disease in Korean population,Empagliflozin,Sitagliptin,Hospitalization for unstable angine,Efficacy,HR,0.99,0.74,1.34,0.94,0.88,1.01,,,,,,,,,,,,
,Jang,2022,https://doi.org/10.3389/fphar.2022.928121,EMPA-REG OUTCOME,NCT01131676,https://doi.org/10.1056/NEJMoa1504720,Adult patients (≥18 years) with type 2 diabetes mellitus and established cardiovascular disease in Korean population,Empagliflozin,Sitagliptin,Coronary revascularization,Efficacy,HR,0.86,0.72,1.04,0.94,0.87,1.02,,,,,,,,,,,,
,Jang,2022,https://doi.org/10.3389/fphar.2022.928121,EMPA-REG OUTCOME,NCT01131676,https://doi.org/10.1056/NEJMoa1504720,Adult patients (≥18 years) with type 2 diabetes mellitus and established cardiovascular disease in Korean population,Empagliflozin,Sitagliptin,Transient ischemic attack,Efficacy,HR,0.85,0.51,1.42,0.88,0.74,1.04,,,,,,,,,,,,
,Jang,2022,https://doi.org/10.3389/fphar.2022.928121,EMPA-REG OUTCOME,NCT01131676,https://doi.org/10.1056/NEJMoa1504720,Adult patients (≥18 years) with type 2 diabetes mellitus and established cardiovascular disease in Korean population,Empagliflozin,Sitagliptin,hospitalization for heart failure,Efficacy,HR,0.65,0.5,0.85,0.85,0.75,0.95,,,,,,,,,,,,
,Jang,2022,https://doi.org/10.3389/fphar.2022.928121,EMPA-REG OUTCOME,NCT01131676,https://doi.org/10.1056/NEJMoa1504720,Adult patients (≥18 years) with type 2 diabetes mellitus and established cardiovascular disease in Korean population,Empagliflozin,Sitagliptin,Hypoglycemic adverse event,Safety,OR,1,0.89,1.11,0.7,0.59,0.84,,,,,,,,,,,,
,Jang,2022,https://doi.org/10.3389/fphar.2022.928121,EMPA-REG OUTCOME,NCT01131676,https://doi.org/10.1056/NEJMoa1504720,Adult patients (≥18 years) with type 2 diabetes mellitus and established cardiovascular disease in Korean population,Empagliflozin,Sitagliptin,Urinary tract infection,Safety,OR,0.99,0.87,1.13,0.87,0.81,0.94,,,,,,,,,,,,
,Jang,2022,https://doi.org/10.3389/fphar.2022.928121,EMPA-REG OUTCOME,NCT01131676,https://doi.org/10.1056/NEJMoa1504720,Adult patients (≥18 years) with type 2 diabetes mellitus and established cardiovascular disease in Korean population,Empagliflozin,Sitagliptin,Genital infection,Safety,OR,3.74,2.7,5.19,1.49,1.35,1.65,,,,,,,,,,,,
,Jang,2022,https://doi.org/10.3389/fphar.2022.928121,EMPA-REG OUTCOME,NCT01131676,https://doi.org/10.1056/NEJMoa1504720,Adult patients (≥18 years) with type 2 diabetes mellitus and established cardiovascular disease in Korean population,Empagliflozin,Sitagliptin,Acute kidney injury,Safety,OR,0.78,0.63,0.96,0.7,0.59,0.82,,,,,,,,,,,,
,Jang,2022,https://doi.org/10.3389/fphar.2022.928121,EMPA-REG OUTCOME,NCT01131676,https://doi.org/10.1056/NEJMoa1504720,Adult patients (≥18 years) with type 2 diabetes mellitus and established cardiovascular disease in Korean population,Empagliflozin,Sitagliptin,Volume depletion,Safety,OR,1.04,0.82,1.3,0.84,0.76,0.94,,,,,,,,,,,,
,Jang,2022,https://doi.org/10.3389/fphar.2022.928121,EMPA-REG OUTCOME,NCT01131676,https://doi.org/10.1056/NEJMoa1504720,Adult patients (≥18 years) with type 2 diabetes mellitus and established cardiovascular disease in Korean population,Empagliflozin,Sitagliptin,Diabetic ketoacidosis,Safety,OR,1.99,0.2,17.8,1.09,0.72,1.64,,,,,,,,,,,,
,Jang,2022,https://doi.org/10.3389/fphar.2022.928121,EMPA-REG OUTCOME,NCT01131676,https://doi.org/10.1056/NEJMoa1504720,Adult patients (≥18 years) with type 2 diabetes mellitus and established cardiovascular disease in Korean population,Empagliflozin,Sitagliptin,Thromboembolic event,Safety,OR,0.75,0.42,1.31,0.92,0.8,1.05,,,,,,,,,,,,
,Jang,2022,https://doi.org/10.3389/fphar.2022.928121,EMPA-REG OUTCOME,NCT01131676,https://doi.org/10.1056/NEJMoa1504720,Adult patients (≥18 years) with type 2 diabetes mellitus and established cardiovascular disease in Korean population,Empagliflozin,Sitagliptin,Fracture,Safety,OR,0.98,0.76,1.27,0.94,0.87,1.03,,,,,,,,,,,,
,Merola,2022,https://doi.org/10.2147/CLEP.S373291,PARSIFAL,NCT02491983,https://doi.org/10.1001/jamaoncol.2021.4301,Women ≥18 years old with metastatic breast cancer,Fulvestrant + Palbociclib,Letrozole + Palbociclib,Overall survival,Efficacy,HR,1,0.68,1.48,1.07,0.86,1.35,,,,,,,,,,,,
,Softness,2022,https://doi.org/10.1016/j.urolonc.2021.12.015,SPARE,ISRCTN61126465,https://doi.org/10.1111/bju.13900,patients aged 40 to 79 with cT2-3cN0cM0 urothelial carcinoma of the bladder,Radical cystectomy (RC) with lymphadenectomy,Trimodality therapy (TMT),Overall survival,Efficacy,HR,3.05,0.92,10.15,0.87,0.64,1.19,,,,,,,,,,,,
,Evans,2023,https://doi.org/10.1371/journal.pone.0268807,MERINO,NCT02176122,https://doi.org/10.1001/jama.2018.12163,Patients with bloodstream infection with E. colior Klebsiella spp. with proven non-susceptibility to third generation cephalosporins and susceptibility to meropenem and piperacillin- tazobactam,Piperacillin-tazobactam 4.5g administered every 6 hours intravenously,Meropenem 1g administered every 8 hours intravenously,all-cause mortality at 25 days,Efficacy,OR,3.69,1.48,10.4,1.31,0.4,4.26,,,,,,,,,,,,
,Gallivan,2023,https://doi.org/10.3928/23258160-20221214-01,VIEW 1,NCT00509795,"https://doi.org/10.1016/j.ophtha.2012.09.006, https://doi.org/10.1136/bjophthalmol-2019-315021",Adult patients (≥50 years) with neovascular age-related macular degeneration (nAMD),RQ4: Monthly ranibizumab injection,IAI 2Q4: Monthly intravitreal aflibercept injection,Mean change in ETDRS BCVA letters,Efficacy,MD,-2.8,-5.11,-0.49,0.9,-0.16,1.96,,,,,,,,,,,,
,Gallivan,2023,https://doi.org/10.3928/23258160-20221214-01,VIEW 1,NCT00509795,"https://doi.org/10.1016/j.ophtha.2012.09.006, https://doi.org/10.1136/bjophthalmol-2019-315021",Adult patients (≥50 years) with neovascular age-related macular degeneration (nAMD),RQ4: Monthly ranibizumab injection,IAI 2Q8: Intravitreal aflibercept every 2 months after 3 initial monthly doses,Mean change in ETDRS BCVA letters,Efficacy,MD,0.2,-2.21,2.61,-1.3,-4.91,2.31,,,,,,,,,,,,
,Gallivan,2023,https://doi.org/10.3928/23258160-20221214-01,VIEW 1,NCT00509795,"https://doi.org/10.1016/j.ophtha.2012.09.006, https://doi.org/10.1136/bjophthalmol-2019-315021",Adult patients (≥50 years) with neovascular age-related macular degeneration (nAMD),RQ4: Monthly ranibizumab injection,IAI 2Q4: Monthly intravitreal aflibercept injection,Mean change in ETDRS BCVA letters,Efficacy,MD,1.8,-0.26,3.86,0.9,-0.16,1.96,,,,,,,,,,,,
,Gallivan,2023,https://doi.org/10.3928/23258160-20221214-01,VIEW 1,NCT00509795,"https://doi.org/10.1016/j.ophtha.2012.09.006, https://doi.org/10.1136/bjophthalmol-2019-315021",Adult patients (≥50 years) with neovascular age-related macular degeneration (nAMD),RQ4: Monthly ranibizumab injection,IAI 2Q8: Intravitreal aflibercept every 2 months after 3 initial monthly doses,Mean change in ETDRS BCVA letters,Efficacy,MD,0.5,-1.69,2.69,-1.3,-4.91,2.31,,,,,,,,,,,,
,Jiao,2023,https://doi.org/10.1093/aje/kwad091,SPRINT,NCT01206062,https://doi.org/10.1056/NEJMoa1511939,Adults with hypertension at high cardiovascular risk (QRISK3 score ≥20%),Intensive blood pressure control strategy (target BP ≤130/80 mm Hg),Standard blood pressure control strategy (target BP ≤140/90 mm Hg),MACE (major adverse cardiovascular events),Efficacy,HR,0.75,0.64,0.89,0.96,0.92,1,,,,,,,,,,,,
,Jiao,2023,https://doi.org/10.1093/aje/kwad091,SPRINT,NCT01206062,https://doi.org/10.1056/NEJMoa1511939,Adults with hypertension at high cardiovascular risk (QRISK3 score ≥20%),Intensive blood pressure control strategy (target BP ≤130/80 mm Hg),Standard blood pressure control strategy (target BP ≤140/90 mm Hg),Myocardial infarction,Efficacy,HR,0.83,0.64,1.09,1,0.93,1.07,,,,,,,,,,,,
,Jiao,2023,https://doi.org/10.1093/aje/kwad091,SPRINT,NCT01206062,https://doi.org/10.1056/NEJMoa1511939,Adults with hypertension at high cardiovascular risk (QRISK3 score ≥20%),Intensive blood pressure control strategy (target BP ≤130/80 mm Hg),Standard blood pressure control strategy (target BP ≤140/90 mm Hg),Stroke,Efficacy,HR,0.89,0.63,1.25,0.95,0.89,1.01,,,,,,,,,,,,
,Jiao,2023,https://doi.org/10.1093/aje/kwad091,SPRINT,NCT01206062,https://doi.org/10.1056/NEJMoa1511939,Adults with hypertension at high cardiovascular risk (QRISK3 score ≥20%),Intensive blood pressure control strategy (target BP ≤130/80 mm Hg),Standard blood pressure control strategy (target BP ≤140/90 mm Hg),Congestive heart failure,Efficacy,HR,0.62,0.45,0.84,1.01,0.96,1.06,,,,,,,,,,,,
,Jiao,2023,https://doi.org/10.1093/aje/kwad091,SPRINT,NCT01206062,https://doi.org/10.1056/NEJMoa1511939,Adults with hypertension at high cardiovascular risk (QRISK3 score ≥20%),Intensive blood pressure control strategy (target BP ≤130/80 mm Hg),Standard blood pressure control strategy (target BP ≤140/90 mm Hg),Death from cardiovascular causes,Efficacy,HR,0.57,0.38,0.85,0.93,0.88,0.97,,,,,,,,,,,,
,Jiao,2023,https://doi.org/10.1093/aje/kwad091,SPRINT,NCT01206062,https://doi.org/10.1056/NEJMoa1511939,Adults with hypertension at high cardiovascular risk (QRISK3 score ≥20%),Intensive blood pressure control strategy (target BP ≤130/80 mm Hg),Standard blood pressure control strategy (target BP ≤140/90 mm Hg),Death from any cause,Efficacy,HR,0.73,0.6,0.9,0.96,0.95,0.98,,,,,,,,,,,,
,Merola,2023,https://doi.org/10.1002/pds.5565,PALOMA-2,NCT01740427,https://doi.org/10.1007/s10549-018-05125-4,"Women aged ≥18 with hormone-positive, HER-2 negative metastatic breast cancer",Palbociclib + letrozole,Letrozole,Time to next treatment (TTNT),Efficacy,HR,0.64,0.52,0.78,0.62,0.56,0.68,,,,,,,,,,,,
,Wakabayashi,2023,https://doi.org/10.1007/s40801-023-00353-7,PRIME-V,UMIN000015170,https://doi.org/10.1111/dom.13750,Japanese adults with T2D treated with sitagliptin,Ipragliflozin,Metformin,Percentage changes in HbA1c levels (%),Efficacy,MD,4.03,0.79,7.27,-6.21,-11.01,-1.4,,,,,,,,,,,,
,Wakabayashi,2023,https://doi.org/10.1007/s40801-023-00353-7,COMPASS,UMIN000004716,https://doi.org/10.1111/dom.12055,Japanese adults with T2D inadequately controlled with metformin and/or sulfonylurea,Sitagliptin,Pioglitazone,"Change in HbA1c, %",Efficacy,MD,-0.28,-0.14,-0.16,-0.01,-0.25,0.23,,,,,,,,,,,,
,Wakabayashi,2023,https://doi.org/10.1007/s40801-023-00353-7,Onishi 2013 et al.,NCT01272193,https://doi.org/10.1111/dom.12097,Insulin-naïve Japanese adults with T2D,Insulin degludec/insulin aspart,Insulin glargine,"Change in HbA1c, %",Efficacy,MD,-0.28,-0.46,-0.1,0.46,-0.01,0.94,,,,,,,,,,,,
,Robak,2024,https://doi.org/10.1080/03007995.2024.2368175,RESONATE-2,NCT01722487,"https://doi.org/10.1056/nejmoa1509388, https://doi.org/10.3324/haematol.2018.192328",Adult patients with chronic lymphocytic leukemia (CLL),First-line (1L) ibrutinib monotherapy,First-line chemotherapy/chemoimmunotherapy (CT/CIT) followed by second-line (2L) ibrutinib after disease progression,Overall survival,Efficacy,HR,0.35,0.2,0.62,0.64,0.39,1.04,,,,,,,,,,,,
,Baptiste,2024,https://doi.org/10.1093/aje/kwae137,ONTARGET,NCT00153101,https://doi.org/10.1056/NEJMoa0801317,"High-risk patients aged ≥55 years with history of either coronary artery, peripheral artery, or cerebrovascular disease, or high-risk diabetes with end organ damage",Angiotensin receptor blocker (ARB),Angiotensin-converting enzyme inhibitor (ACEi),"Primary composite: Death from cardiovascular causes, myocardial infarction, stroke, or hospitalisation for heart failure",Efficacy,HR,1.01,0.94,1.09,0.98,0.94,1.02,,,,,,,,,,,,
,Baptiste,2024,https://doi.org/10.1093/aje/kwae137,ONTARGET,NCT00153101,https://doi.org/10.1056/NEJMoa0801317,"High-risk patients aged ≥55 years with history of either coronary artery, peripheral artery, or cerebrovascular disease, or high-risk diabetes with end organ damage",Angiotensin receptor blocker (ARB),Angiotensin-converting enzyme inhibitor (ACEi),"Main secondary outcome: Death from cardiovascular causes, myocardial infarction or stroke",Efficacy,HR,0.99,0.91,1.07,0.98,0.94,1.02,,,,,,,,,,,,
,Baptiste,2024,https://doi.org/10.1093/aje/kwae137,ONTARGET,NCT00153101,https://doi.org/10.1056/NEJMoa0801317,"High-risk patients aged ≥55 years with history of either coronary artery, peripheral artery, or cerebrovascular disease, or high-risk diabetes with end organ damage",Angiotensin receptor blocker (ARB),Angiotensin-converting enzyme inhibitor (ACEi),Myocardial infarction,Efficacy,HR,1.07,0.94,1.22,0.97,0.92,1.01,,,,,,,,,,,,
,Baptiste,2024,https://doi.org/10.1093/aje/kwae137,ONTARGET,NCT00153101,https://doi.org/10.1056/NEJMoa0801317,"High-risk patients aged ≥55 years with history of either coronary artery, peripheral artery, or cerebrovascular disease, or high-risk diabetes with end organ damage",Angiotensin receptor blocker (ARB),Angiotensin-converting enzyme inhibitor (ACEi),Stroke,Efficacy,HR,0.91,0.79,1.05,1.04,0.97,1.12,,,,,,,,,,,,
,Baptiste,2024,https://doi.org/10.1093/aje/kwae137,ONTARGET,NCT00153101,https://doi.org/10.1056/NEJMoa0801317,"High-risk patients aged ≥55 years with history of either coronary artery, peripheral artery, or cerebrovascular disease, or high-risk diabetes with end organ damage",Angiotensin receptor blocker (ARB),Angiotensin-converting enzyme inhibitor (ACEi),Hospitalisation for heart failure,Efficacy,HR,1.12,0.97,1.29,0.97,0.9,1.05,,,,,,,,,,,,
,Baptiste,2024,https://doi.org/10.1093/aje/kwae137,ONTARGET,NCT00153101,https://doi.org/10.1056/NEJMoa0801317,"High-risk patients aged ≥55 years with history of either coronary artery, peripheral artery, or cerebrovascular disease, or high-risk diabetes with end organ damage",Angiotensin receptor blocker (ARB),Angiotensin-converting enzyme inhibitor (ACEi),Death from cardiovascular causes,Efficacy,HR,1,0.89,1.12,0.96,0.9,1.03,,,,,,,,,,,,
,Baptiste,2024,https://doi.org/10.1093/aje/kwae137,ONTARGET,NCT00153101,https://doi.org/10.1056/NEJMoa0801317,"High-risk patients aged ≥55 years with history of either coronary artery, peripheral artery, or cerebrovascular disease, or high-risk diabetes with end organ damage",Angiotensin receptor blocker (ARB),Angiotensin-converting enzyme inhibitor (ACEi),Death from non-cardiovascular causes,Efficacy,HR,0.96,0.83,1.1,0.97,0.92,1.02,,,,,,,,,,,,
,Baptiste,2024,https://doi.org/10.1093/aje/kwae137,ONTARGET,NCT00153101,https://doi.org/10.1056/NEJMoa0801317,"High-risk patients aged ≥55 years with history of either coronary artery, peripheral artery, or cerebrovascular disease, or high-risk diabetes with end organ damage",Angiotensin receptor blocker (ARB),Angiotensin-converting enzyme inhibitor (ACEi),Death from any cause,Efficacy,HR,0.98,0.9,1.07,0.97,0.93,1.01,,,,,,,,,,,,
,Baptiste,2024,https://doi.org/10.1093/aje/kwae137,ONTARGET,NCT00153101,https://doi.org/10.1056/NEJMoa0801317,"High-risk patients aged ≥55 years with history of either coronary artery, peripheral artery, or cerebrovascular disease, or high-risk diabetes with end organ damage",Angiotensin receptor blocker (ARB),Angiotensin-converting enzyme inhibitor (ACEi),Cough,Safety,RR,0.26,0.21,0.33,1.29,1.16,1.43,,,,,,,,,,,,
,Baptiste,2024,https://doi.org/10.1093/aje/kwae137,ONTARGET,NCT00153101,https://doi.org/10.1056/NEJMoa0801317,"High-risk patients aged ≥55 years with history of either coronary artery, peripheral artery, or cerebrovascular disease, or high-risk diabetes with end organ damage",Angiotensin receptor blocker (ARB),Angiotensin-converting enzyme inhibitor (ACEi),Angioedema,Safety,RR,0.4,0.19,0.86,1.14,0.72,1.8,,,,,,,,,,,,
,Baptiste,2024,https://doi.org/10.1093/aje/kwae137,ONTARGET,NCT00153101,https://doi.org/10.1056/NEJMoa0801317,"High-risk patients aged ≥55 years with history of either coronary artery, peripheral artery, or cerebrovascular disease, or high-risk diabetes with end organ damage",Angiotensin receptor blocker (ARB),Angiotensin-converting enzyme inhibitor (ACEi),≥30% increase in serum creatinine,Safety,RR,1.14,0.8,1.62,1.38,1.34,1.43,,,,,,,,,,,,
,Goriacko,2024,https://doi.org/10.1093/ajhp/zxae161,REMAP-CAP,NCT02735707,https://doi.org/10.1056/NEJMoa2100433,Critically ill patients with COVID-19,tocilizumab,no tocilizumab,28-day all-cause mortality,Efficacy,OR,0.76,0.66,0.88,0.86,0.52,1.44,,,,0.65,0.43,0.99,0.77,0.68,0.87,,,
,Szmulewicz,2024,https://doi.org/10.1093/aje/kwae029,EUFEST,ISRCTN68736636,https://doi.org/10.1016/S0140-6736(08)60486-9,"Individuals aged 18-40 with a diagnosis of schizophrenia, schizophreniform, or schizoaffective disorder",olanzapine 5-30 mg,"First-generation agents: haloperidol 5-10 mg, f luphenazine 2.5-40 mg, perphenazine 4-64 mg",12-month risks of discontinuation,Efficacy,HR,0.28,0.18,0.43,0.32,0.24,0.43,,,,,,,,,,,,
,Szmulewicz,2024,https://doi.org/10.1093/aje/kwae029,EUFEST,ISRCTN68736636,https://doi.org/10.1016/S0140-6736(08)60486-9,"Individuals aged 18-40 with a diagnosis of schizophrenia, schizophreniform, or schizoaffective disorder",quetiapine 200-750 mg,"First-generation agents: haloperidol 5-10 mg, f luphenazine 2.5-40 mg, perphenazine 4-64 mg",12-month risks of discontinuation,Efficacy,HR,0.52,0.36,0.76,0.41,0.28,0.59,,,,,,,,,,,,
,Szmulewicz,2024,https://doi.org/10.1093/aje/kwae029,EUFEST,ISRCTN68736636,https://doi.org/10.1016/S0140-6736(08)60486-9,"Individuals aged 18-40 with a diagnosis of schizophrenia, schizophreniform, or schizoaffective disorder",olanzapine 5-30 mg,"First-generation agents: haloperidol 5-10 mg, f luphenazine 2.5-40 mg, perphenazine 4-64 mg",Severity of illness score (CGI-S),Efficacy,MD,-0.6,-1.431,0.231,-0.3,-0.676,0.076,,,,,,,,,,,,
,Szmulewicz,2024,https://doi.org/10.1093/aje/kwae029,EUFEST,ISRCTN68736636,https://doi.org/10.1016/S0140-6736(08)60486-9,"Individuals aged 18-40 with a diagnosis of schizophrenia, schizophreniform, or schizoaffective disorder",quetiapine 200-750 mg,"First-generation agents: haloperidol 5-10 mg, f luphenazine 2.5-40 mg, perphenazine 4-64 mg",Severity of illness score (CGI-S),Efficacy,MD,-0.1,-0.931,0.731,-0.5,-0.923,-0.077,,,,,,,,,,,,
,Szmulewicz,2024,https://doi.org/10.1093/aje/kwae029,EUFEST,ISRCTN68736636,https://doi.org/10.1016/S0140-6736(08)60486-9,"Individuals aged 18-40 with a diagnosis of schizophrenia, schizophreniform, or schizoaffective disorder",olanzapine 5-30 mg,"First-generation agents: haloperidol 5-10 mg, f luphenazine 2.5-40 mg, perphenazine 4-64 mg",Overall functioning score (GAF),Efficacy,MD,4,-4.429,12.429,3.2,-3.11,9.51,,,,,,,,,,,,
,Szmulewicz,2024,https://doi.org/10.1093/aje/kwae029,EUFEST,ISRCTN68736636,https://doi.org/10.1016/S0140-6736(08)60486-9,"Individuals aged 18-40 with a diagnosis of schizophrenia, schizophreniform, or schizoaffective disorder",quetiapine 200-750 mg,"First-generation agents: haloperidol 5-10 mg, f luphenazine 2.5-40 mg, perphenazine 4-64 mg",Overall functioning score (GAF),Efficacy,MD,-0.1,-9.802,9.702,2.7,-3.84,9.24,,,,,,,,,,,,
,Szmulewicz,2024,https://doi.org/10.1093/aje/kwae029,EUFEST,ISRCTN68736636,https://doi.org/10.1016/S0140-6736(08)60486-9,"Individuals aged 18-40 with a diagnosis of schizophrenia, schizophreniform, or schizoaffective disorder",olanzapine 5-30 mg,"First-generation agents: haloperidol 5-10 mg, f luphenazine 2.5-40 mg, perphenazine 4-64 mg",Admission to hospital after intake,Efficacy,RR,0.909,0.698,1.184,1.006,0.755,1.34,,,,,,,,,,,,
,Szmulewicz,2024,https://doi.org/10.1093/aje/kwae029,EUFEST,ISRCTN68736636,https://doi.org/10.1016/S0140-6736(08)60486-9,"Individuals aged 18-40 with a diagnosis of schizophrenia, schizophreniform, or schizoaffective disorder",quetiapine 200-750 mg,"First-generation agents: haloperidol 5-10 mg, f luphenazine 2.5-40 mg, perphenazine 4-64 mg",Admission to hospital after intake,Efficacy,RR,1.045,0.803,1.361,1.1146,0.782,1.589,,,,,,,,,,,,
,Szmulewicz,2024,https://doi.org/10.1093/aje/kwae029,EUFEST,ISRCTN68736636,https://doi.org/10.1016/S0140-6736(08)60486-9,"Individuals aged 18-40 with a diagnosis of schizophrenia, schizophreniform, or schizoaffective disorder",olanzapine 5-30 mg,"First-generation agents: haloperidol 5-10 mg, f luphenazine 2.5-40 mg, perphenazine 4-64 mg",Co-prescription of mood stabilizers,Efficacy,RR,0.96,0.743,1.24,1.589,0.955,2.644,,,,,,,,,,,,
,Szmulewicz,2024,https://doi.org/10.1093/aje/kwae029,EUFEST,ISRCTN68736636,https://doi.org/10.1016/S0140-6736(08)60486-9,"Individuals aged 18-40 with a diagnosis of schizophrenia, schizophreniform, or schizoaffective disorder",quetiapine 200-750 mg,"First-generation agents: haloperidol 5-10 mg, f luphenazine 2.5-40 mg, perphenazine 4-64 mg",Co-prescription of mood stabilizers,Efficacy,RR,1,0.767,1.305,1.74,1.029,2.918,,,,,,,,,,,,
,Szmulewicz,2024,https://doi.org/10.1093/aje/kwae029,EUFEST,ISRCTN68736636,https://doi.org/10.1016/S0140-6736(08)60486-9,"Individuals aged 18-40 with a diagnosis of schizophrenia, schizophreniform, or schizoaffective disorder",olanzapine 5-30 mg,"First-generation agents: haloperidol 5-10 mg, f luphenazine 2.5-40 mg, perphenazine 4-64 mg",Co-prescription of antidepressants,Efficacy,RR,1.611,1.169,2.221,0.5826,0.395,0.855,,,,,,,,,,,,
,Szmulewicz,2024,https://doi.org/10.1093/aje/kwae029,EUFEST,ISRCTN68736636,https://doi.org/10.1016/S0140-6736(08)60486-9,"Individuals aged 18-40 with a diagnosis of schizophrenia, schizophreniform, or schizoaffective disorder",quetiapine 200-750 mg,"First-generation agents: haloperidol 5-10 mg, f luphenazine 2.5-40 mg, perphenazine 4-64 mg",Co-prescription of antidepressants,Efficacy,RR,0.333,0.208,0.536,0.807,0.541,1.208,,,,,,,,,,,,
,Signori,2024,https://doi.org/10.1136/jnnp-2023-332603,TRANSFORMS,NCT00340834,https://doi.org/10.1056/NEJMoa0907839,Patients aged 18-55 years with relapsing-remitting multiple sclerosis (RRMS),Fingolimod (FTY) 0.5mg daily,Intramuscular interferon β-1a (IFN) 30μg weekly,Annual relapse rate,Efficacy,RR,0.49,0.37,0.64,0.55,0.45,0.68,,,,,,,,,,,,
,Matthews,2024,https://doi.org/10.1007/s10654-024-01119-3,REDUCE-AMI,NCT03278509,https://doi.org/10.1093/ehjcvp/pvac070,Adults ≥18 years with type 1 myocardial infarction,Long-term oral beta blockers,No beta blockers,death or recurrent myocardial infarction,Efficacy,HR,0.96,0.79,1.16,0.78,0.59,1.12,,,,,,,,,,,,
,Wang,2023,https://doi.org/10.1001/jama.2023.4221,LEADER,NCT01179048,https://doi.org/10.1007/s13300-018-0524-z,,Liraglutide,Dipeptidyl peptidase 4 inhibitors (DPP4i),"Composite of nonfatal stroke, nonfatal myocardial infarction, and cardiovascular death (3p MACE)",Efficacy,HR,0.87,0.78,0.97,0.82,0.76,0.87,,,,,,,,,,,,
,Wang,2023,https://doi.org/10.1001/jama.2023.4221,DECLARE-TIMI58,NCT01730534,https://doi.org/10.1056/nejmoa1812389,,Dapagliflozin,Dipeptidyl peptidase 4 inhibitors (DPP4i),Hospitalization for heart failure + cardiovascular death,Efficacy,HR,0.83,0.73,0.95,0.69,0.59,0.81,,,,,,,,,,,,
,Wang,2023,https://doi.org/10.1001/jama.2023.4221,EMPA-REG,NCT01131676,https://doi.org/10.1056/nejmoa1504720,,Empagliflozin,Dipeptidyl peptidase 4 inhibitors (DPP4i),"Composite of nonfatal stroke, nonfatal myocardial infarction, and cardiovascular death (3p MACE)",Efficacy,HR,0.86,0.74,0.99,0.83,0.73,0.95,,,,,,,,,,,,
,Wang,2023,https://doi.org/10.1001/jama.2023.4221,CANVAS,NCT01032629,https://doi.org/10.1056/nejmoa1611925,,Canagliflozin,Dipeptidyl peptidase 4 inhibitors (DPP4i),"Composite of nonfatal stroke, nonfatal myocardial infarction, and cardiovascular death (3p MACE)",Efficacy,HR,0.86,0.75,0.97,0.77,0.7,0.85,,,,,,,,,,,,
,Wang,2023,https://doi.org/10.1001/jama.2023.4221,CARMELINA,NCT01897532,https://doi.org/10.1001/jama.2018.18269,,Linagliptin,Sulfonylureas,"Composite of nonfatal stroke, nonfatal myocardial infarction, and cardiovascular death (3p MACE)",Efficacy,HR,1.02,0.89,1.17,0.9,0.84,0.96,,,,,,,,,,,,
,Wang,2023,https://doi.org/10.1001/jama.2023.4221,TECOS,NCT00790205,https://doi.org/10.1056/nejmoa1501352,,Sitagliptin,Sulfonylureas,"Composite of nonfatal stroke, nonfatal myocardial infarction, and cardiovascular death (3p MACE) + angina",Efficacy,HR,0.98,0.88,1.09,0.89,0.86,0.91,,,,,,,,,,,,
,Wang,2023,https://doi.org/10.1001/jama.2023.4221,SAVOR-TIMI,NCT01107886,https://doi.org/10.1056/nejmoa1307684,,Saxagliptin,Sulfonylureas,"Composite of nonfatal stroke, nonfatal myocardial infarction, and cardiovascular death (3p MACE)",Efficacy,HR,1,0.89,1.12,0.81,0.76,0.86,,,,,,,,,,,,
,Wang,2023,https://doi.org/10.1001/jama.2023.4221,LEAD-2,NCT00318461,https://doi.org/10.2337/dc08-1355,,Liraglutide + metformin,Glimepiride + metformin,Hemoglobin A1c,Efficacy,MD,0,-0.2,0.2,0.05,-0.11,0.22,,,,,,,,,,,,
,Wang,2023,https://doi.org/10.1001/jama.2023.4221,TRITON-TIMI,NCT00097591,https://doi.org/10.1056/nejmoa0706482,,Prasugrel,Clopidogrel,"Composite of nonfatal stroke, nonfatal myocardial infarction, and cardiovascular death (3p MACE)",Efficacy,HR,0.81,0.73,0.9,0.88,0.79,0.97,,,,,,,,,,,,
,Wang,2023,https://doi.org/10.1001/jama.2023.4221,PLATO,NCT00391872,https://doi.org/10.1056/nejmoa0904327,,Ticagrelor,Clopidogrel,"Composite of nonfatal stroke, nonfatal myocardial infarction, and cardiovascular death (3p MACE)",Efficacy,HR,0.84,0.77,0.92,0.92,0.83,1.02,,,,,,,,,,,,
,Wang,2023,https://doi.org/10.1001/jama.2023.4221,ISAR-REACT 5,NCT01944800,https://doi.org/10.1056/nejmoa1908973,,Prasugrel,Ticagrelor,"All cause death, non-fatal myocardial infarction, stroke",Efficacy,HR,1.36,1.09,1.7,NA,NA,NA,,,,,,,,,,,,
,Wang,2023,https://doi.org/10.1001/jama.2023.4221,ARISTOTLE,NCT00412984,https://doi.org/10.1056/nejmoa1107039,,Apixaban,Warfarin,Stroke/Systemic Embolism,Efficacy,HR,0.79,0.66,0.95,0.68,0.61,0.76,,,,,,,,,,,,
,Wang,2023,https://doi.org/10.1001/jama.2023.4221,RE-LY,NCT00262600,https://doi.org/10.1056/nejmoa0905561,,Dabigatran,Warfarin,Stroke/Systemic Embolism,Efficacy,HR,0.66,0.53,0.82,0.73,0.6,0.9,,,,,,,,,,,,
,Wang,2023,https://doi.org/10.1001/jama.2023.4221,ROCKET AF,NCT00403767,https://doi.org/10.1056/nejmoa1009638,,Rivaroxaban,Warfarin,Stroke/Systemic Embolism,Efficacy,HR,0.79,0.66,0.96,0.7,0.62,0.8,,,,,,,,,,,,
,Wang,2023,https://doi.org/10.1001/jama.2023.4221,EINSTEIN DVT,NCT00440193,https://doi.org/10.1056/nejmoa1007903,,Rivaroxaban,Warfarin,Venous thromboembolism,Efficacy,HR,0.68,0.44,1.04,0.75,0.62,0.9,,,,,,,,,,,,
,Wang,2023,https://doi.org/10.1001/jama.2023.4221,EINSTEIN PE,NCT00439725,https://doi.org/10.1056/nejmoa1007903,,Rivaroxaban,Warfarin,Venous thromboembolism,Efficacy,HR,1.12,0.75,1.68,0.67,0.55,0.8,,,,,,,,,,,,
,Wang,2023,https://doi.org/10.1001/jama.2023.4221,RE-COVER II,NCT00680186,https://doi.org/10.1161/circulationaha.113.004450,,Dabigatran,Warfarin,Venous thromboembolism / Venous thromboembolism Related Death,Efficacy,HR,1.08,0.64,1.8,1.15,0.74,1.78,,,,,,,,,,,,
,Wang,2023,https://doi.org/10.1001/jama.2023.4221,AMPLIFY,NCT00643201,https://doi.org/10.1056/nejmoa1302507,,Apixaban,Warfarin,Venous thromboembolism / Venous thromboembolism Related Death,Efficacy,HR,0.84,0.6,1.18,0.81,0.54,1.23,,,,,,,,,,,,
,Wang,2023,https://doi.org/10.1001/jama.2023.4221,RECORD1,NCT00329628,https://doi.org/10.1056/nejmoa0800374,,Rivaroxaban,Enoxaparin,"Deep vein thrombosis, pulmonary embolism, death",Efficacy,HR,0.25,0.14,0.47,0.17,0.1,0.29,,,,,,,,,,,,
,Wang,2023,https://doi.org/10.1001/jama.2023.4221,TRANSCEND,NCT00153101,https://doi.org/10.1016/s0140-6736(08)61242-8,,Telmisartan+Loop/CCB/TZ,Loop/CCB/TZ,"Composite of nonfatal stroke, nonfatal myocardial infarction, and cardiovascular death (3p MACE) + Hospitalization for heart failure",Efficacy,HR,0.92,0.81,1.05,0.88,0.83,0.96,,,,,,,,,,,,
,Wang,2023,https://doi.org/10.1001/jama.2023.4221,ONTARGET,NCT00153101,https://doi.org/10.1056/nejmoa0801317,,Telmisartan,Ramipril,"Composite of nonfatal stroke, nonfatal myocardial infarction, and cardiovascular death (3p MACE) + Hospitalization for heart failure",Efficacy,HR,1.01,0.94,1.09,0.83,0.77,0.9,,,,,,,,,,,,
,Wang,2023,https://doi.org/10.1001/jama.2023.4221,HORIZON-PFT,NCT00049829,https://doi.org/10.1056/nejmoa067312,,Zoledronic Acid,Raloxifene,Hip Fracture,Efficacy,HR,0.59,0.42,0.83,0.72,0.55,0.94,,,,,,,,,,,,
,Wang,2023,https://doi.org/10.1001/jama.2023.4221,VERO,NCT01709110,https://doi.org/10.1016/s0140-6736(17)32137-2,,Teriparatide,Risedronate,Vertebral fracture,Efficacy,HR,0.44,0.29,0.68,NA,NA,NA,,,,,,,,,,,,
,Wang,2023,https://doi.org/10.1001/jama.2023.4221,DAPA-CKD,NCT03036150,https://doi.org/10.1056/nejmoa2024816,,Dapagliflozin,Sitagliptin,End stage renal disease / death,Efficacy,HR,0.61,0.51,0.72,0.8,0.52,1.26,,,,,,,,,,,,
,Wang,2023,https://doi.org/10.1001/jama.2023.4221,PARADIGM-HF,NCT01035255,https://doi.org/10.1056/nejmoa1409077,,Sacubitril/Valsartan,Angiotensin-converting enzyme inhibitor,Hospitalization for heart failure / mortality,Efficacy,HR,0.8,0.73,0.87,1.02,0.91,1.14,,,,,,,,,,,,
,Wang,2023,https://doi.org/10.1001/jama.2023.4221,P04334,NCT00383240,https://doi.org/10.2500/aap.2010.31.3364,,Mometasone furoate / formoterol,Formoterol,Asthma exacerbation,Efficacy,HR,0.54,0.44,0.72,0.78,0.62,0.97,,,,,,,,,,,,
,Wang,2023,https://doi.org/10.1001/jama.2023.4221,D5896,NCT01444430,https://doi.org/10.1056/nejmoa1511190,,Budesonide + formoterol,Budenoside,"Asthma related death, intubation, hospitalization",Efficacy,HR,1.07,0.7,1.65,1.38,0.9,2.13,,,,,,,,,,,,
,Wang,2023,https://doi.org/10.1001/jama.2023.4221,IMPACT,NCT02164513,https://doi.org/10.1056/nejmoa1713901,,"Fluticasone, umeclidinium, vilanterol","Fluticasone, vilanterol",Moderate or severe COPD exacerbation,Efficacy,HR,0.85,0.8,0.9,1.13,1.04,1.23,,,,,,,,,,,,
,Wang,2023,https://doi.org/10.1001/jama.2023.4221,POET-COPD,NCT00563381,https://doi.org/10.1056/nejmoa1008378,,Tiotropium,Salmeterol,Moderate or severe COPD exacerbation,Efficacy,HR,0.83,0.77,0.9,1.02,0.93,1.12,,,,,,,,,,,,
,Wang,2023,https://doi.org/10.1001/jama.2023.4221,INSPIRE,NCT00361959,https://doi.org/10.1164/rccm.200707-973oc,,Advair,Tiotropium,COPD exacerbation,Efficacy,HR,0.97,0.84,1.12,0.93,0.9,0.96,,,,,,,,,,,,
,Wang,2023,https://doi.org/10.1001/jama.2023.4221,CAROLINA,NCT01243424,https://doi.org/10.1001/jama.2019.13772,,Linagliptin,Glimepiride,"Composite of nonfatal stroke, nonfatal myocardial infarction, and cardiovascular death (3p MACE)",Efficacy,HR,0.95,0.84,1.14,0.91,0.79,1.05,,,,,,,,,,,,
,Wang,2023,https://doi.org/10.1001/jama.2023.4221,PRONOUNCE,NCT02663908,https://doi.org/10.1161/circulationaha.121.056810,,Degarelix,Leuprolide,"Composite of nonfatal stroke, nonfatal myocardial infarction, and cardiovascular death (3p MACE)",Efficacy,HR,1.28,0.59,2.79,1.35,0.94,1.93,,,,,,,,,,,,